Estrogen Receptor Negative Recruiting Phase 0 Trials for Celecoxib (DB00482)

IndicationStatusPhase
DBCOND0036417 (Estrogen Receptor Negative)Recruiting0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03599453Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerTreatment